News & Updates

Show Multimedia Only
Neoadjuvant cycles do not alter perioperative nivolumab benefit in resectable NSCLC
Neoadjuvant cycles do not alter perioperative nivolumab benefit in resectable NSCLC
19 Apr 2024
Subcutaneous atezolizumab favoured over intravenous infusion
Subcutaneous atezolizumab favoured over intravenous infusion
18 Apr 2024 byJairia Dela Cruz

Nonsmall cell lung cancer (NSCLC) patients with high PD-L1 expression appear to show a strong preference for receiving atezolizumab subcutaneously rather than intravenously.

Subcutaneous atezolizumab favoured over intravenous infusion
18 Apr 2024